Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Immunology
Volume 2018, Article ID 1623957, 4 pages
https://doi.org/10.1155/2018/1623957
Case Report

Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review

1Department of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
2Clinical Oncology Department, Assiut University, Asyut, Egypt
3Medical Oncology Department, South Egypt Cancer Institute, Asyut, Egypt

Correspondence should be addressed to Jawaher Ansari; moc.liamg@irasna.kaj

Received 17 January 2018; Revised 18 April 2018; Accepted 15 May 2018; Published 13 June 2018

Academic Editor: Christian Drouet

Copyright © 2018 Jawaher Ansari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  2. RJ. Motzer, NM. Tannir, DF. McDermott, O. Arén Frontera, B. Melichar, TK. Choueiri et al., “Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma,” New England Journal of Medicine, vol. 378, no. 14, pp. 1277–1290, 2018. View at Google Scholar
  3. I. Ishikawa, “Kovacs G,” incidence of papillary renal cell tumors in patients on chronic haemodialysis, vol. 22, no. 2, p. 135, 1993. View at Google Scholar
  4. M. I. Carlo and D. R. Feldman, “Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis,” European Urology, vol. 70, no. 6, pp. 1082-1083, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Tabei, I. Natsume, and K. Kobayashi, “Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment,” International Journal of Urology, vol. 24, no. 9, pp. 708–710, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ong, A. M. Ibrahim, S. Bourassa-Blanchette, C. Canil, T. Fairhead, and G. Knoll, “Antitumor activity of nivolumab on hemodialysis after renal allograft rejection,” Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 2016. View at Google Scholar · View at Scopus
  7. D. Josephs, T. E. Hutson, C. L. Cowey et al., “Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis,” BJU International, vol. 108, no. 8, pp. 1279–1283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Casper, D. Goebel, V. Gruenwald et al., “Efficacy and safety of sunitinib in patients with metastatic renal cell carcinoma on hemodialysis.,” Journal of Clinical Oncology, vol. 29, no. 15_suppl, pp. 4646–4646, 2011. View at Publisher · View at Google Scholar
  9. A. V. Shetty, M. R. Matrana, B. J. Atkinson, A. L. Flaherty, E. Jonasch, and N. M. Tannir, “Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: A single institution experience,” Clinical Genitourinary Cancer, vol. 12, no. 5, pp. 348–353, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Guida, C. Masini, M. Milella et al., “Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis,” Future Oncology, vol. 11, no. 23, pp. 3159–3166, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Leonetti, M. Bersanelli, B. Castagneto et al., “Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review,” Clinical Genitourinary Cancer, vol. 14, no. 4, pp. 277–283, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Guida, L. Cosmai, F. Gelsomino, C. Masini, R. Sabbatini, and C. Porta, “Targeted agents in patients with metastatic renal cell carcinoma on dialysis: myths and reality,” European Medical Journal Nephrology, vol. 4, no. 1, pp. 66–77, 2016. View at Google Scholar
  13. R. J. Motzer, B. Escudier, and D. F. McDermott, “Nivolumab versus everolimus in advanced renal-cell carcinoma,” The New England Journal of Medicine, vol. 373, no. 19, pp. 1803–1813, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Bajaj, X. Wang, S. Agrawal, M. Gupta, A. Roy, and Y. Feng, “Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients with Solid Tumors,” CPT: Pharmacometrics & Systems Pharmacology, vol. 6, no. 1, pp. 58–66, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Agrawal, Y. Feng, A. Roy, G. Kollia, and B. Lestini, “Nivolumab dose selection: Challenges, opportunities, and lessons learned for cancer immunotherapy,” Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 2016. View at Google Scholar · View at Scopus